GB Patent

GB2572737A — Use of cannabinoids in the treatment of epilepsy

Assigned to GW Research Ltd · Expires 2019-10-16 · 7y expired

What this patent protects

Cannabidiol (CBD) for use in the reduction of seizures in treatment-resistant epilepsy (TRE) is provided, wherein the CBD is administered in combination with an antiepileptic drug (AED) that works via GABA receptor agonism, preferably stiripentol. The CBD is preferably administer…

USPTO Abstract

Cannabidiol (CBD) for use in the reduction of seizures in treatment-resistant epilepsy (TRE) is provided, wherein the CBD is administered in combination with an antiepileptic drug (AED) that works via GABA receptor agonism, preferably stiripentol. The CBD is preferably administered in combination with stiripentol and clobazam. The CBD may be present as a synthetic compound or may be in the form of a highly purified extract of cannabis which comprises at least 98% (w/w) CBD, less than 0.15% tetrahydrocannabinol (THC), and up to 1% cannabidivarin (CBDV). The dose of CBD is preferably below 50mg/kg/day. Preferably the treatment-resistant epilepsy is Lennox-Gastaut syndrome or Dravet syndrome.

Drugs covered by this patent

Patent Metadata

Patent number
GB2572737A
Jurisdiction
GB
Classification
—
Expires
2019-10-16
Drug substance claim
No
Drug product claim
No
Assignee
GW Research Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.